These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts
Suven Life Sciences (Suven) announced the grant of a product patent from Mexico (325948) and one from Singapore (180674) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these Patents are valid through 2029.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 18 granted patents from Mexico and 20 granted patents from Singapore. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally” said Venkat Jasti, Chief Executive Officer, Suven Life Sciences.
The company has 11 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, huntington’s disease, parkinson’s disease and obesity in addition to phase II ready developmental candidate SUVN-502 for and phase I candidate SUVN-G3031 for Alzheimer’s disease and Schizophrenia.
Comments are closed.